Assuming risk is required, the following results were found.

  • Fooling nerve cells into acting normal

    Discovery could inform future studies related to spinal cord injuries, multiple sclerosis and epilepsy Date:Source:University of Missouri-ColumbiaSummary:Scientists have discovered that a neuron's own electrical signal, or voltage, can indicate whether...

    https://mschristian.org/index.php/blog/fooling-nerve-cells-into-acting-normal
  • #ECTRIMS2019 – Tysabri During Pregnancy and After Delivery Seems Safe, Reduces Relapse Risk, Study Finds

    and News Continuing Tysabri (natalizumab) treatment up to week 28 of pregnancy, and restarting soon after birth, reduces the risk of relapses in women with multiple sclerosis and appears to be safe for the mother and the baby, new research suggests....

    https://mschristian.org/index.php/blog/ectrims2019-tysabri-during-pregnancy-and-after-delivery-seems-safe-reduces-relapse-risk-study-finds
  • Can Anti-TNF Drugs Reduce Alzheimer's Risk?

    Systemic inflammatory diseases involving tumor necrosis factor (TNF) increased the risk of Alzheimer's disease, but that risk was reduced in patients who used anti-TNF biologics, an analysis of 56 million adults' electronic health records showed. While...

    https://mschristian.org/index.php/blog/can-anti-tnf-drugs-reduce-alzheimer-s-risk
  • MS Risk Nearly Doubles 15 Years Following Teen Concussion - Medscape

    STOCKHOLM — People who experience a concussion during adolescence are at significantly elevated risk for multiple sclerosis (MS) later in life, especially 15 years or more following their head trauma, a large retrospective study suggests. This risk for...

    https://mschristian.org/index.php/blog/ms-risk-nearly-doubles-15-years-following-teen-concussion-medscape
  • Mechanism controlling multiple sclerosis risk identified

    predisposed individuals. Researchers at Karolinska Institutet in Sweden have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective...

    https://mschristian.org/index.php/blog/mechanism-controlling-multiple-sclerosis-risk-identified
  • Tecfidera (dimethyl fumarate)

    relapsing forms of multiple sclerosis (MS). Tecfidera is classified as a disease-modifying therapy for MS. It reduces the risk of MS relapse by up to 49 percent over two years. It also reduces the risk of having worsening physical disability by about 38...

    https://mschristian.org/index.php/blog/tecfidera-dimethyl-fumarate
  • EMA committee recommends caution in use of tofacitinib owing to increased risk of blood clots - The Pharmaceutical Journal

    Medicinal Products for Human Use (CHMP) has endorsed recommendations that tofacitinib (Xeljanz; Pfizer) could increase the risk of blood clots in the lungs and should be used with caution in all patients already at high risk. Tofacitinib is indicated...

    https://mschristian.org/index.php/blog/ema-committee-recommends-caution-in-use-of-tofacitinib-owing-to-increased-risk-of-blood-clots-the-pharmaceutical-journal
  • MS genes formerly missing-in-action have been found

    all the genes? Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving...

    https://mschristian.org/index.php/blog/ms-genes-formerly-missing-in-action-have-been-found
  • Aubagio (teriflunomide)

    to treat rheumatoid arthritis. Your doctor will give you blood tests before and while you take Aubagio to check your liver.Risk of birth defects. If you're pregnant, you shouldn't take Aubagio because it may cause major birth defects. If you might...

    https://mschristian.org/index.php/blog/aubagio-teriflunomide
  • Genentech’s Satralizumab Significantly Reduced Relapse Risk in Second Positive Phase III Study for Neuromyelitis Optica Spectrum Disorder

    Pivotal Phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented at ECTRIMS Congress 2019 74% reduction in the risk of relapse for satralizumab monotherapy versus placebo in people with...

    https://mschristian.org/index.php/blog/genentech-s-satralizumab-significantly-reduced-relapse-risk-in-second-positive-phase-iii-study-for-neuromyelitis-optica-spectrum-disorder
  • New insights into how immune system and inflammation play a role in PD

    studies, suggest quite strongly that individuals with an increased tendency for peripheral inflammation have a higher risk to acquire PD. Given the potentially critical role of gut pathology in the pathogenesis of PD, there is reason to suspect that IBD...

    https://mschristian.org/index.php/blog/new-insights-into-how-immune-system-and-inflammation-play-a-role-in-pd
  • International MS Genetics Consortium Confirms 233 MS-Related Gene Variations in Largest Study to Date

    people with MS and 68,374 individuals without MS.They confirmed 233 variations in the human genome that contribute to the risk of developing MS. The variations were found to influence many different immune cell types and tissues, indicating that broad...

    https://mschristian.org/index.php/blog/international-ms-genetics-consortium-confirms-233-ms-related-gene-variations-in-largest-study-to-date
  • #ECTRIMS2019 - Longer DMT Use and Female Sex Seen to Protect Against SPMS Conversion - Multiple Sclerosis News Today

    and Research in Multiple Sclerosis (ECTRIMS) running through Friday in Stockholm. His presentation was titled “Defining the risk factors for the conversion to secondary progressive multiple sclerosis: a retrospective cohort study of the Italian MS...

    https://mschristian.org/index.php/blog/ectrims2019-longer-dmt-use-and-female-sex-seen-to-protect-against-spms-conversion-multiple-sclerosis-news-today
  • Scientists Find Missing-In-Action Multiple Sclerosis Genes

    all the genes? Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving...

    https://mschristian.org/index.php/blog/scientists-find-missing-in-action-multiple-sclerosis-genes
  • Disability progression in multiple sclerosis linked to income, education

    Neighbourhood income and education level is associated with risk of disability progression in patients with multiple sclerosis, suggests new research from the University of British Columbia. UBC researchers, along with colleagues in Wales, compared...

    https://mschristian.org/index.php/blog/disability-progression-in-multiple-sclerosis-linked-to-income-education
  • Siponimod Delays Time to Wheelchair in Secondary Progressive MS - Neurology Times

    patients with a baseline EDSS of 6.5 progressed to a score of ≥7, compared to 26.1% of placebo patients, equating to a risk reduction of 36% (hazard ratio [HR], 0.64; 95% CI, 0.41–1.0; P = .0483). In the multistate model, a similar reduction of 21% risk...

    https://mschristian.org/index.php/blog/siponimod-delays-time-to-wheelchair-in-secondary-progressive-ms-neurology-times
  • DOUBT Study Clarifies Role of MRI for TIA or Stroke

    Addressed: What was the rate of stroke defined by diffusion restriction detected on MRI scans among patients with low-risk suspected transient ischemic attack (TIA) or minor stroke presentations? Study Synopsis and Perspective: Patients with low-risk...

    https://mschristian.org/index.php/blog/doubt-study-clarifies-role-of-mri-for-tia-or-stroke
  • Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) | Small Molecules | News Channels - PipelineReview.com

    study in a broad SPMS patient population (EDSS score 3.0 to 6.5 at baseline), showing Mayzent significantly reduced the risk of disease progression, including physical disability and cognitive decline[2]Up to 80% of patients with relapsing remitting...

    https://mschristian.org/index.php/blog/novartis-receives-positive-chmp-opinion-for-mayzent-siponimod-for-the-treatment-of-adult-patients-with-active-secondary-progressive-multiple-sclerosis-spms-small-molecules-news-channels-pipelinereview-com
  • Leading Suicide Prevention Organization and Correctional Health Care Experts Release Suicide Prevention Resource Guide - P&T Community

    – a serious problem in the United States. "Research tells us that people in times of transition are at especially high risk for suicide, and incarcerated people are particularly vulnerable due to health and situational reasons," said Robert Gebbia, CEO...

    https://mschristian.org/index.php/blog/leading-suicide-prevention-organization-and-correctional-health-care-experts-release-suicide-prevention-resource-guide-p-t-community
  • "Treating MS: A Simplified Strategy Boosts Patient and Provider Satisfaction"

    brain and spinal cord damage sets a poor long-term trajectory. It is not the clinician’s job to be paternal and decide what risk a patient should or should not be exposed to. Instead, it is the clinician’s ethical obligation to educate the patient on...

    https://mschristian.org/index.php/blog/treating-ms-a-simplified-strategy-boosts-patient-and-provider-satisfaction

Results 1 - 20 of 109
 
 

Follow Us on Twitter

Follow Us On Twitter - Image